MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

31.33 -0.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.42

Max

31.55

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+71.85% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	472M 2.1B
Vorige openingsprijs	31.36
Vorige sluitingsprijs	31.33

Nieuwssentiment

By Acuity

100%

332 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2026, 17:26 UTC

Belangrijke Nieuwsgebeurtenissen

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 apr 2026, 23:55 UTC

Marktinformatie

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Market Talk Roundup: Latest on U.S. Politics

7 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 apr 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 apr 2026, 23:42 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 apr 2026, 23:42 UTC

Marktinformatie

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:15 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 apr 2026, 23:04 UTC

Belangrijke Nieuwsgebeurtenissen

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 apr 2026, 23:04 UTC

Belangrijke Nieuwsgebeurtenissen

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 apr 2026, 23:03 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 apr 2026, 23:03 UTC

Marktinformatie

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 apr 2026, 22:58 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

7 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 apr 2026, 19:45 UTC

Marktinformatie

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 apr 2026, 19:17 UTC

Belangrijke Nieuwsgebeurtenissen

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 apr 2026, 19:16 UTC

Marktinformatie

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 apr 2026, 19:07 UTC

Marktinformatie

Global Energy Roundup: Market Talk

7 apr 2026, 19:07 UTC

Marktinformatie

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 apr 2026, 18:41 UTC

Acquisities, Fusies, Overnames

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 apr 2026, 18:40 UTC

Acquisities, Fusies, Overnames

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 apr 2026, 18:39 UTC

Acquisities, Fusies, Overnames

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 apr 2026, 18:24 UTC

Belangrijke Nieuwsgebeurtenissen

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 17:08 UTC

Marktinformatie

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 apr 2026, 16:21 UTC

Belangrijke Nieuwsgebeurtenissen

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

71.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.91 USD 71.85%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.